A Matched Case-Control Study of a Novel Acid-Pump Antagonist and Proton-Pump Inhibitor for the Treatment of latrogenic Ulcers Caused by Endoscopic Submucosal Dissection

作者：Kim Yong Gil; Jang Byung Ik^*; Kim Tae Nyeun

来源：Gut and Liver, 2010, 4(1): 25-30.

DOI：10.5009/gnl.2010.4.1.25

• Revaprazan
• Rabeprazole
• Proton pump inhibitors
• Acid pump antagonists
• Endoscopic submucosal dissection

Background/Aims: Revaprazan, a novel acid-pump antagonist, and proton-pump inhibitors (PPIs) have pH-independent effects on ulcer healing. The addition of a PPI promotes the cell restitution rate as well as vessel regeneration and maturation for ulcer repair. Revaprazan is known to protect the mucosa by increasing the prostaglandin concentration. Methods: We reviewed the medical records of patients who underwent endoscopic submucosal dissection (ESD) for gastric neoplasia at Yeungnam University Hospital between January 2008 and May 2009. We conducted a matched case-control study to compare the healing rates effected by revaprazan and rabeprazole. Results: Each group consisted of 30 patients. The baseline characteristics did not differ significantly between the two groups. Stage S1 disease was observed in 97% and 100% of patients after 8 weeks of treatment in the revaprazan and rabeprazole groups, respectively. In the revaprazan group, only one patient had stage H2 disease: a 54-year-old man with a 5.5-cm lesion after ESD of the ulcer, type Ila early gastric cancer, and adenocarcinoma. No serious adverse effects occurred during the treatment period in either group. Conclusions: The safety and efficacy profiles of revaprazan and rabeprazole are similar for the treatment of ESD-induced ulcers. (Gut Liver 2010; 4:25-30)

• 出版日期2010-3